ProVise Management Group LLC lessened its position in Celgene Co. (NASDAQ:CELG) by 14.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,728 shares of the biopharmaceutical company’s stock after selling 1,813 shares during the quarter. ProVise Management Group LLC’s holdings in Celgene were worth $1,564,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Thompson Davis & CO. Inc. increased its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI increased its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Guidant Wealth Advisors bought a new position in shares of Celgene during the 3rd quarter worth about $119,000. Motco increased its holdings in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Penserra Capital Management LLC bought a new position in shares of Celgene during the 2nd quarter worth about $129,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.
Several research analysts have recently issued reports on the stock. Piper Jaffray Companies restated a “hold” rating and set a $104.00 price objective on shares of Celgene in a report on Thursday. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 price objective on the stock in a report on Wednesday. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the stock a “hold” rating in a report on Wednesday. Mizuho restated a “buy” rating and set a $128.00 price objective on shares of Celgene in a report on Wednesday. Finally, Guggenheim restated a “buy” rating and set a $147.00 price objective on shares of Celgene in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $129.98.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 earnings per share. equities research analysts predict that Celgene Co. will post 6.7 EPS for the current year.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.